Corcept Strategy and Business Model

Executive Overview

Corcept is a commercial-stage biopharmaceutical company focused on cortisol modulation: developing and commercializing drugs that block or selectively modulate the effects of cortisol in serious disease. Founded in 1998 and headquartered in Redwood City, California, Corcept sits at the intersection of rare endocrinology and specialty drug development. Its current business is built around Korlym, a branded form of mifepristone approved in the United States for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not surgical candidates or have not achieved cure with surgery. That commercial franchise funds a broader proprietary pipeline led by relacorilant, a selective glucocorticoid receptor antagonist being developed in Cushing’s syndrome and oncology.

Strategically, Corcept is distinctive because it is not a typical pre-revenue biotech. It already has a meaningful commercial base, yet it is still trying to evolve into a multi-asset cortisol-biology company. Its commercial footprint is primarily U.S.-based, while clinical development and manufacturing rely heavily on third-party partners. Annual revenue is generated almost entirely from Korlym, with the most recent reported annual revenue shown in the live data table below.

Corcept at a Glance

Logo
Common name	Corcept
Full legal name	Corcept Therapeutics Incorporated
Headquarters	Redwood City, California, United States
Ownership	Public company (Nasdaq: CORT)
Ticker	CORT
Exchange	NASDAQ
Market Cap	$8.56B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1998; went public in 2004; Korlym received U.S. Food and Drug Administration approval in 2012; later expanded into a relacorilant-led proprietary pipeline in endocrinology and oncology.
Industry or industries	Biopharmaceuticals; rare endocrine disorders; oncology drug development
Key products or services	Korlym; discovery, development, and planned commercialization of selective cortisol modulators led by relacorilant
Geographic footprint	Primarily U.S. commercialization; global clinical-trial and third-party manufacturing partner network
Business segments as officially reported	One reportable segment
Company website	https://www.corcept.com

1. What Is the Strategy of Corcept?

1a. What is the winning aspiration of Corcept?

Corcept’s winning aspiration, based on its public filings and investor communications through 2024, is to become the leading company focused on cortisol modulation. In practical terms, winning means more than maximizing near-term Korlym prescriptions. Corcept is trying to build a durable franchise around glucocorticoid receptor biology: first by expanding diagnosis and treatment of endogenous Cushing’s syndrome, then by turning proprietary compounds into additional approved products in endocrinology and oncology. Management has generally emphasized clinical, regulatory, and commercial execution milestones rather than a formal long-range revenue target. The strategic aspiration is scientific leadership plus profitable growth.
1b. Where does Corcept play?

Corcept plays in a deliberately narrow field. Commercially, it focuses on patients with endogenous Cushing’s syndrome, especially those with hyperglycemia, and on the specialist physicians who diagnose and treat them. The company does not try to serve broad primary care markets. In development, it chooses diseases where abnormal cortisol signaling may matter clinically and where a glucocorticoid receptor antagonist or modulator could produce differentiated outcomes. As of 2024, that includes Cushing’s syndrome and selected oncology settings, most notably platinum-resistant ovarian cancer. Geographically, the revenue base is still primarily U.S.-centered even though clinical trials and supply relationships can extend internationally.
1c. How does Corcept plan to win?

Corcept plans to win through focused differentiation rather than scale. In today’s market, it combines a specialized product, physician education around underdiagnosis, and high-touch reimbursement support aimed at a small prescriber base. In the pipeline, its main differentiator is selectivity. Relacorilant was designed to modulate the glucocorticoid receptor without the progesterone receptor activity associated with mifepristone, which could matter for tolerability, drug interactions, and use in oncology combinations. A second part of the recipe is financial: Korlym cash flow helps fund R&D, reducing dependence on external capital compared with many development-stage biotech peers.
1d. What capabilities must Corcept have in place?

To execute this strategy, Corcept needs a narrow set of strong capabilities: deep cortisol-biology research, disciplined clinical development in rare endocrinology and oncology, regulatory expertise, intellectual-property management, rare-disease commercial execution, reimbursement and patient-support capabilities, and strong oversight of third-party manufacturers and clinical vendors. Because Corcept does not operate like a large integrated pharmaceutical company, vendor management and program prioritization are especially important capabilities.
1e. What management systems does Corcept require?

Corcept requires management systems that reinforce focus and control risk. That includes portfolio-governance processes for deciding which cortisol-modulator programs to advance, compliance systems for Good Clinical Practice and current Good Manufacturing Practice oversight, pharmacovigilance and medical-safety systems, metrics for prescriber adoption and reimbursement approvals, and capital-allocation discipline that balances near-term Korlym growth against long-cycle R&D investment. For a company with one commercial asset and multiple pipeline bets, these systems matter as much as the science.

2. What Are the Current Strategic Initiatives of Corcept?

Expand the Korlym franchise by improving diagnosis and treatment rates. A central initiative in Corcept’s public messaging has been that hypercortisolism remains underdiagnosed. The company continues to invest in physician education, referral-network development, and patient-access support to identify more appropriate patients and help specialists navigate reimbursement. This is less about mass-market promotion and more about systematically widening the diagnosed and treated population.
Advance relacorilant in endogenous Cushing’s syndrome. Corcept’s most important product-development initiative is late-stage development of relacorilant for Cushing’s syndrome. Strategically, this is not just a second product opportunity. It is also a chance to move the company from a branded mifepristone franchise toward a proprietary next-generation cortisol-modulation platform.
Execute the relacorilant oncology program, especially in platinum-resistant ovarian cancer. Corcept has publicly highlighted the Phase 3 ROSELLA trial of relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer. If successful, this would materially broaden Corcept’s addressable market and shift part of the company into oncology commercialization.
Build a broader proprietary pipeline around cortisol biology. Beyond relacorilant, Corcept has continued to develop additional cortisol-modulating compounds in neurologic, metabolic, and other settings. The strategic goal is to avoid being a one-product company and to reuse a coherent scientific platform across multiple diseases.
Maintain a self-funded growth model. Unlike many small biotech companies, Corcept has had the ability to fund major portions of development from commercial operations. Preserving that flexibility by growing Korlym while investing heavily in R&D is a strategic initiative in its own right.
Prepare the organization for a potentially more complex launch portfolio. If relacorilant reaches the market in endocrinology or oncology, Corcept will need different launch, medical-affairs, market-access, and supply capabilities. Readiness for that transition appears to be an important behind-the-scenes initiative.

3. What Is the Business Model of Corcept?

Corcept’s current business model is straightforward: it earns revenue from sales of a branded specialty pharmaceutical product, Korlym, and uses the cash generated by that franchise to fund internal discovery, clinical development, and the build-out required for future launches.

What customers actually buy: Today, customers effectively buy access to Korlym therapy for a narrow patient population with endogenous Cushing’s syndrome and hyperglycemia, together with the reimbursement support, education, and patient-service infrastructure needed to get the therapy started and maintained.
Recurring or repeat-driven versus one-time: The model is heavily repeat-driven. Korlym is not a one-time procedure or device sale; it is a chronic specialty-drug therapy, so revenue depends on patient starts, persistence, adherence, and duration of treatment.
How pricing power works: Corcept has some pricing power because it sells into a rare-disease setting with significant unmet need and limited direct branded competition. That said, pricing power is not unlimited. Payers, prior authorization, formulary controls, and clinical alternatives all matter, especially as more therapies for hypercortisolism become available.
Why the business mix matters: Today’s mix is highly concentrated. Nearly all commercial revenue comes from one product in one main disease area. That concentration creates operating leverage when Korlym grows, but it also creates concentration risk. The strategic importance of relacorilant is therefore outsized.
What drives gross margin, operating margin, and cash generation: As with many specialty-pharma companies, unit manufacturing cost for an oral small-molecule product is low relative to net selling price, so the business can generate attractive gross margins. Operating margin is then determined largely by how much Corcept chooses to invest in R&D, medical affairs, and specialist commercial infrastructure. Cash generation is helped by low capital-expenditure needs because manufacturing is outsourced.
Revenue model: This is a branded prescription-drug model, not subscription, freemium, or rental. Revenue is recognized from product sales, with future upside tied to additional product approvals and possibly broader prescriber bases.

4. What Products and/or Services Does Corcept Sell?

Korlym. Korlym is Corcept’s only approved commercial product and the company’s current revenue engine. It is approved in the United States for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery. It is the product that drives essentially all current revenue, profit, and cash generation.
Relacorilant. Relacorilant is Corcept’s lead proprietary development asset and its most strategically important pipeline program. It is a selective glucocorticoid receptor antagonist being developed in endogenous Cushing’s syndrome and in oncology, including platinum-resistant ovarian cancer. If approved, it could materially change Corcept’s business mix.
Additional cortisol modulators. Corcept has other proprietary compounds in earlier-stage development across cortisol-related disease areas. These programs matter strategically because they test whether the company can build a pipeline platform rather than remain a single-product business.
Related commercial services. Corcept is not a services company in the traditional sense, but its offering includes patient-support, reimbursement-navigation, and specialist-education activities that are essential to the commercial model.

The clearest distinction in Corcept’s portfolio is between the current commercial franchise and the proprietary growth pipeline. Korlym is the incumbent cash generator; relacorilant is the pipeline asset with the greatest strategic importance.

5. What Are the Key Competitors or Peers of Corcept?

Corcept does not face a long list of direct company-level rivals in its current commercial niche. The more accurate framing is a mix of direct competitors in Cushing’s syndrome, clinical substitutes, and future oncology comparators.

Recordati Rare Diseases — A direct endocrine competitor through products used in Cushing’s disease, including Isturisa and Signifor-branded therapies. Recordati is one of the most relevant commercial rivals in the hypercortisolism treatment landscape.
Xeris Biopharma — A direct competitor through Recorlev, an approved treatment for endogenous Cushing’s syndrome. Xeris matters because it competes for the same specialist prescribers and patients.
Surgery, radiation, and bilateral adrenalectomy — These are clinical substitutes rather than company competitors, but they are strategically important because definitive treatment can reduce or eliminate long-term drug use in some patients.
Generic steroidogenesis inhibitors such as ketoconazole and metyrapone — These are therapy substitutes often used off-label or in particular regional practices. They matter because physicians compare mechanism, safety, tolerability, and reimbursement across classes.
AbbVie, through the ELAHERE franchise acquired with ImmunoGen — Not a current Cushing’s competitor, but relevant to Corcept’s future oncology ambitions because ELAHERE is an approved therapy in a defined segment of platinum-resistant ovarian cancer.
Merck & Co. — A future oncology comparator given the importance of combination regimens and immunotherapy in solid tumors where Corcept is exploring cortisol modulation.
AstraZeneca — Another oncology peer relevant to ovarian-cancer treatment pathways and clinical-development competition, even if not a direct cortisol-biology rival.
Neurocrine Biosciences and Crinetics Pharmaceuticals — These are best viewed as business-model comparables rather than direct competitors. Both illustrate how focused endocrine or neuroendocrine biopharma companies can build specialist commercial organizations and leverage science-driven pipelines.

The main point is that Corcept’s competitive position today is shaped more by therapeutic alternatives and specialist prescribing dynamics than by a broad peer set of identical companies.

6. What Is the Marketing Strategy of Corcept?

Corcept’s marketing strategy is best understood as specialist medical marketing, not mass-market brand advertising. The company sells into a rare-disease environment where physician awareness, accurate diagnosis, and reimbursement support matter more than broad consumer reach.

Disease-awareness and education: A major marketing objective is to help physicians recognize hypercortisolism earlier and identify patients who may be appropriate for treatment.
Targeted physician engagement: Corcept appears to focus on endocrinologists, referral centers, and high-value prescribers rather than broad office-based coverage.
Medical and scientific credibility: Publications, conference presence, and medical-affairs activity are likely more important than consumer advertising.
Access support as part of marketing execution: In specialty pharma, market access and patient-start support are inseparable from marketing effectiveness. Corcept’s ability to translate physician intent into filled prescriptions is a practical differentiator.

Marketing is therefore a supporting capability rather than the core strategic moat. The deeper moat is Corcept’s focused science and rare-disease commercial execution, but marketing still matters because the treated population depends on diagnosis.

7. What Are the Key Customer Segments of Corcept?

Endocrinologists and specialist prescribers. These are the key commercial decision-makers today because Korlym is prescribed in a narrow endocrine setting.
Academic medical centers and referral hubs. Complex Cushing’s patients are often concentrated in specialist centers, making these institutions disproportionately important.
Patients with endogenous Cushing’s syndrome and hyperglycemia. This is the ultimate end-market, though patients usually access therapy through physician prescribing and payer approval rather than direct purchase decisions.
Payers and pharmacy benefit managers. They are not end users, but they materially influence access, persistence, and net pricing.
Future oncology customers. If relacorilant is approved in oncology, Corcept’s customer base would broaden to oncologists, cancer centers, and infusion-setting stakeholders.

Corcept is not diversified across many end markets today. Its current business is concentrated in one rare-disease area, which creates focus and customer intimacy but also concentration risk.

8. What Is the Sales Model of Corcept?

Corcept uses a high-touch specialty-pharma sales model.

Direct specialist sales: The company sells through its own field organization calling on endocrinologists and relevant specialist accounts.
Specialty distribution: Therapy reaches patients through a managed specialty-pharmacy model rather than broad retail distribution.
Patient-start and reimbursement support: Benefits investigation, prior authorization support, and case management are important parts of getting a prescription converted into ongoing therapy.
Medical-affairs overlay: In a specialist market, medical science and field education play a large role alongside commercial selling.

This channel structure creates strong customer intimacy because the number of relevant prescribers is limited and each relationship can matter. It also means growth depends less on advertising scale and more on territory design, physician targeting, referral development, and payer execution. If Corcept launches in oncology, its sales model may need to evolve because oncology accounts, treatment pathways, and site-of-care economics differ from endocrinology.

9. In What Geographies Does Corcept Operate?

Corcept’s commercial business is primarily U.S.-based. Public materials consistently emphasize the United States as the core market for Korlym. The company is headquartered in Redwood City, California and does not present itself as a broad multinational commercial pharmaceutical company.

Its operating footprint is wider than its revenue footprint, however. Clinical trials may involve sites outside the United States, and Corcept relies on third-party manufacturers and service providers that can be located in multiple countries. Even so, the company remains geographically concentrated compared with large pharmaceutical peers. That concentration has two implications: first, execution in the U.S. market matters disproportionately; second, international expansion remains more of an option value than a core current driver.

10. Who Are the Owners of Corcept?

Corcept is a publicly traded company listed on Nasdaq under the ticker CORT. As of 2024 public ownership disclosures, the shareholder base appeared to be primarily institutional, with large asset managers such as Vanguard and BlackRock among significant holders. Insiders, including founder and Chief Executive Officer Joseph K. Belanoff, have also held meaningful stakes. Corcept does not appear to have a publicly disclosed controlling shareholder, so ownership is best understood as widely held and time-sensitive based on market activity and regulatory filings.

11. How Is Corcept Organized?

Officially, Corcept reports one reportable segment. That is typical for a focused biopharmaceutical company whose commercial and development activities are tightly linked.

At a practical level, the company can be understood as having several functional layers:

Commercial operations centered on Korlym, including field sales, reimbursement support, and patient services.
Research and development covering discovery, translational science, clinical development, biostatistics, and regulatory affairs.
Medical affairs and safety for physician engagement, publications, and pharmacovigilance.
Technical operations overseeing outsourced manufacturing, supply planning, and quality systems.
Corporate functions such as finance, legal, intellectual property, human resources, and investor relations.

The important point is that Corcept’s reporting structure is simpler than its operating reality. The business may be one segment for reporting, but managing a marketed rare-disease therapy and a late-stage oncology and endocrine pipeline requires different rhythms and capabilities.

12. How Does Corcept Operate?

Day to day, Corcept operates as a focused biopharmaceutical company with a hybrid model: core science, clinical strategy, and commercial direction are internal, while much of manufacturing and trial execution is externalized.

Discover and prioritize compounds. Corcept identifies and advances cortisol-modulating molecules that fit its biological thesis.
Run clinical development. It designs and oversees studies in endocrinology and oncology, typically with support from contract research organizations, trial sites, and specialist vendors.
Manage regulatory and safety work. As a drug developer and commercial company, Corcept must maintain rigorous regulatory compliance, label support, and pharmacovigilance.
Oversee outsourced manufacturing. It does not rely on a large network of owned plants; instead it manages third-party suppliers for active ingredients, finished dose production, packaging, and quality.
Commercialize through a specialist model. Corcept educates physicians, supports patient access, works through specialty distribution, and monitors refill and persistence dynamics.
Recycle cash flow into pipeline investment. The company’s operating model is designed so the commercial business helps fund future product candidates.

The main operational complexities are not factory utilization or retail scale. They are diagnosis bottlenecks, clinical-trial execution, payer access, third-party quality oversight, and the challenge of evolving from a one-product company into a broader specialty-pharma platform.

13. What Are the Growth Opportunities for Corcept?

Expand the treated Cushing’s population. The most immediate growth opportunity is to diagnose more appropriate patients and deepen use of Korlym within the existing labeled setting. This is a commercial-execution opportunity more than a new-market opportunity.
Launch relacorilant in endogenous Cushing’s syndrome if clinical and regulatory milestones are met. This could diversify the product base, refresh the endocrine franchise, and give Corcept a proprietary successor asset rather than relying solely on branded mifepristone.
Enter oncology with relacorilant. Success in platinum-resistant ovarian cancer would be strategically significant because it would open a much larger specialty market and demonstrate that cortisol modulation has utility beyond endocrinology.
Advance additional cortisol-modulator indications. Corcept’s broader platform gives it optionality in metabolic, neurologic, and other disease areas where cortisol signaling may be relevant.
Selective geographic expansion or partnering. Corcept’s commercial business is still heavily U.S.-concentrated. Over time, ex-U.S. commercialization or licensing could become a meaningful growth lever if management decides the economics are attractive.

The main constraints are equally clear: clinical-trial risk, regulatory uncertainty, payer friction, competition in hypercortisolism, dependence on one current revenue source, and the execution challenge of entering oncology without losing focus.

14. What Is the History of Corcept?

1998: Corcept was founded to develop drugs based on cortisol biology, with psychiatrist and researcher Joseph Belanoff playing a central role in its creation.
2004: The company went public, giving it access to capital to fund research and clinical development.
Early years: Corcept explored cortisol modulation in psychiatric indications, including psychotic depression. Those efforts helped establish the scientific platform, even though they did not become the company’s lasting commercial business.
2012: Korlym received U.S. Food and Drug Administration approval, a turning point that transformed Corcept from a purely developmental biotech into a commercial company.
2010s: Corcept built a specialist commercial organization around Cushing’s syndrome and used the product’s success to strengthen its balance sheet.
2020s: The company expanded its proprietary pipeline, especially relacorilant, and increasingly positioned itself as a broader cortisol-modulation company spanning endocrinology and oncology.

Corcept’s history is notable because its growth has been largely organic. It has not depended on serial large acquisitions; instead it has tried to compound a focused scientific thesis over time.

15. What Are the Key Suppliers to Corcept?

Suppliers are strategically important to Corcept because the company relies heavily on external partners rather than owning a large integrated manufacturing network. Public filings typically do not emphasize a long list of named suppliers, but the important supplier categories are clear.

Active pharmaceutical ingredient and finished-dose manufacturers. These suppliers are essential for Korlym production and for clinical supply of pipeline candidates.
Packaging and quality-testing partners. In specialty pharma, release testing, stability work, labeling, and packaging accuracy are critical.
Contract research organizations and clinical-service vendors. These partners support site management, monitoring, data handling, and operational execution of clinical trials.
Central laboratories and specialized diagnostic vendors. These suppliers matter because endocrine and oncology studies depend on consistent biomarker and safety data.
Specialty-pharmacy and distribution partners. These channel partners help convert prescriptions into therapy starts and ongoing patient access.

Supplier structure matters because Corcept’s ability to grow is tied not just to demand, but also to reliable compliant execution by third parties. Quality lapses or supply interruptions at partners can have outsized effects on a focused product portfolio.

16. How Does the Supply Chain of Corcept Function?

Corcept’s supply chain is typical of a specialty biopharma company with outsourced manufacturing. It begins with sourcing active ingredients and production services through third-party manufacturers operating under current Good Manufacturing Practice. Finished products are then packaged, quality-released, and moved through controlled specialty distribution channels rather than a broad retail pharmacy network.

For Korlym, the supply chain must support a relatively small but medically important patient population where stockouts or reimbursement delays can disrupt continuity of care. For the pipeline, the supply chain also includes clinical-trial material planning, comparator procurement where relevant, site logistics, and close coordination with contract research organizations and trial sites.

Strategically, supply-chain reliability matters for three reasons: first, Corcept has limited room for disruption because of its product concentration; second, the company depends on quality and timing from third parties; and third, any future launch in oncology or additional endocrine indications would increase operational complexity.

17. What Are the Key Assets of Corcept?

Corcept is not especially asset-heavy in the sense of owning large manufacturing plants, fleets, or retail networks. Its most important assets are intangible, regulatory, scientific, and commercial.

The Korlym franchise. The approved product, its label, its prescriber relationships, and its reimbursement know-how are the company’s core commercial assets.
Proprietary cortisol-modulator intellectual property. Corcept’s compounds, patents, and know-how around glucocorticoid receptor biology are central to its long-term value.
Clinical data and development programs. The relacorilant program in particular is a major strategic asset because it could redefine the company’s future business mix.
Cash and internally generated funding capacity. For a small biotech, a self-funded or largely self-funded model is itself a strategic asset.
Specialist commercial infrastructure. Relationships with endocrinologists, referral centers, payers, and specialty pharmacies are difficult to replicate quickly.

These assets create barriers to entry that are more about science, execution, and regulatory position than about hard physical infrastructure.

18. What Is the R&D Strategy of Corcept?

Corcept’s R&D strategy is concentrated rather than sprawling. The company does not attempt to be a broad multi-mechanism biotech. Instead, it focuses on one biological domain: diseases in which cortisol signaling and glucocorticoid receptor activity are important.

The key strategic idea is to move from mifepristone, which validates the commercial relevance of glucocorticoid receptor antagonism, toward selective proprietary compounds that may offer cleaner pharmacology or better fit for additional settings. Relacorilant is the clearest expression of that strategy. It is designed to avoid progesterone receptor binding, which is strategically meaningful because it could improve tolerability and expand use in combination regimens, including oncology.

Corcept also appears to favor a platform logic in R&D: reuse scientific expertise across endocrinology, oncology, and other cortisol-related diseases while staying close to a coherent mechanism. That focus reduces scientific sprawl, though it also increases dependence on one core hypothesis. In practice, the R&D strategy requires disciplined trial selection, biomarker reasoning, and willingness to stop programs that do not support the platform.

19. What Is the Finance Strategy of Corcept?

Corcept’s finance strategy appears built around self-funded growth, balance-sheet flexibility, and selective reinvestment. That is notable because many biotech companies rely heavily on external equity financing; Corcept has had the advantage of a commercial product that can generate substantial cash.

Prioritize liquidity and strategic flexibility. Strong cash generation gives Corcept room to fund trials, absorb clinical setbacks better than many peers, and prepare for additional launches.
Reinvest in R&D and commercialization. The company’s main use of capital is operating investment rather than large fixed-asset spending.
Keep capital intensity low. Because manufacturing is outsourced, capital expenditure needs are relatively modest. The key financial decisions are about trial pacing, sales-force investment, market access, and portfolio prioritization.
Maintain a simple capital structure. Corcept is better understood as a reinvestment story than an income story. It has not built its equity case around dividends or heavy leverage.

Finance strategy is therefore tightly linked to corporate strategy: preserve the cash engine, invest in relacorilant and other pipeline assets, and avoid taking on complexity or financial commitments that reduce optionality.

20. How Companies Like Corcept Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Corcept use Umbrex when they need top-tier strategic and functional talent without hiring a full consulting team and carrying the associated overhead. For a focused specialty-biopharma company, that is often especially useful when the workload is high-stakes but episodic: a launch decision, a channel redesign, a portfolio review, or a supply-chain risk project.

Representative projects Umbrex consultants could support for a company like Corcept include:

Rare-disease diagnosis funnel strategy: map the referral and diagnosis pathway for endogenous Cushing’s syndrome and identify interventions to increase appropriate patient starts.
Relacorilant launch readiness for endocrinology: define target product positioning, prescriber segmentation, patient-support design, and field-force requirements ahead of a potential launch.
Oncology commercialization strategy: assess go-to-market options, account targeting, and channel economics if relacorilant reaches the market in platinum-resistant ovarian cancer.
Payer access and reimbursement optimization: redesign prior authorization workflows, hub operations, and specialty-pharmacy coordination to improve time to therapy.
Portfolio prioritization: build a fact-based framework for allocating R&D dollars across relacorilant and earlier-stage cortisol-modulator programs.
Commercial operating model design: determine how Corcept should evolve from a one-product endocrine company into a multi-product specialty-pharma organization.
Supply-chain and contract-manufacturing risk review: evaluate single-source exposure, quality-system resilience, inventory strategy, and clinical-supply readiness.
International market assessment: analyze which non-U.S. markets may justify direct entry, partnering, or licensing for Korlym or future assets.
Field-force sizing and territory optimization: refine specialist coverage, key-opinion-leader mapping, and account prioritization in rare endocrinology and possible oncology expansion.
Data, analytics, and AI use cases: identify practical analytics opportunities in patient services, demand forecasting, medical-information workflows, or trial-operations support.